title: MDM2 promotes proteasomal degradation of p21Waf1 via a conformation change.
authors.affiliation: Division of Clinical Pharmacology, Department of Pharmacology and Toxicology, University of Alabama at Birmingham, Birmingham, Alabama 35294, USA.
authors.forename: Hongxia
authors.initials: H
authors.lastname: Xu
authors.forename: Zhuo
authors.initials: Z
authors.lastname: Zhang
authors.forename: Mao
authors.initials: M
authors.lastname: Li
authors.forename: Ruiwen
authors.initials: R
authors.lastname: Zhang
mesh_terms: D017209:Apoptosis; D002453:Cell Cycle; D045744:Cell Line, Tumor; D050759:Cyclin-Dependent Kinase Inhibitor p21 / Q000378:metabolism; D031541:Fluorescence Resonance Energy Transfer / Q000379:methods; D005982:Glutathione Transferase / Q000378:metabolism; D006801:Humans; D009369:Neoplasms / Q000378:metabolism; D046988:Proteasome Endopeptidase Complex / Q000378:metabolism; D011487:Protein Conformation; D025941:Protein Interaction Mapping; D017434:Protein Structure, Tertiary; D051736:Proto-Oncogene Proteins c-mdm2 / Q000378:metabolism*; D015398:Signal Transduction; D025801:Ubiquitin / Q000737:chemistry
chemical_list: D050759:Cyclin-Dependent Kinase Inhibitor p21; D025801:Ubiquitin; C497206:MDM2 protein, human; D051736:Proto-Oncogene Proteins c-mdm2; D005982:Glutathione Transferase; D046988:Proteasome Endopeptidase Complex